Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 2
2013 1
2014 1
2015 1
2016 2
2019 4
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?
Burkhardt B, Lenz G. Burkhardt B, et al. Hematol Oncol. 2015 Jun;33 Suppl 1:62-6. doi: 10.1002/hon.2219. Hematol Oncol. 2015. PMID: 26062057 Review.
Is there anything that we can learn from each other regarding paediatric and adult non-Hodgkin Lymphoma (NHL) management? Do we treat the same patients? ...The far lower absolute number of patients, especially of relapsed patients, and the favorable ou …
Is there anything that we can learn from each other regarding paediatric and adult non-Hodgkin Lymphoma (NHL) ma …
Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ, Chu Y, Hanley PJ, Cairo MS. Barth MJ, et al. Br J Haematol. 2016 May;173(4):597-616. doi: 10.1111/bjh.14078. Epub 2016 Apr 7. Br J Haematol. 2016. PMID: 27062282 Free article. Review.
The following review describes the current state of immunotherapy for non-Hodgkin lymphoma including a summary of currently available data and promising agents currently in clinical development with future promise in the treatment of childhood, adolescent and young adul …
The following review describes the current state of immunotherapy for non-Hodgkin lymphoma including a summary of currently available data a …
Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
Metzger ML, Mauz-Körholz C. Metzger ML, et al. Br J Haematol. 2019 Jun;185(6):1142-1157. doi: 10.1111/bjh.15789. Epub 2019 Feb 6. Br J Haematol. 2019. PMID: 30729493 Free article. Review.
The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th …
The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during th …
Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
Chu Y, Gardenswartz A, Termuhlen AM, Cairo MS. Chu Y, et al. Br J Haematol. 2019 Jun;185(6):1055-1070. doi: 10.1111/bjh.15753. Epub 2019 Jan 6. Br J Haematol. 2019. PMID: 30613939 Free PMC article. Review.
This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therap …
This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell tran …
Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort.
Mezger NCS, Hämmerl L, Griesel M, Seraphin TP, Joko-Fru YW, Feuchtner J, Zietsman A, Péko JF, Tadesse F, Buziba NG, Wabinga H, Nyanchama M, Chokunonga E, Kéita M, N'da G, Lorenzoni CF, Akele-Akpo MT, Mezger JM, Binder M, Liu B, Bauer M, Henke O, Jemal A, Kantelhardt EJ. Mezger NCS, et al. Oncologist. 2023 Nov 2;28(11):e1017-e1030. doi: 10.1093/oncolo/oyad157. Oncologist. 2023. PMID: 37368350 Free PMC article.
Herein, we examined treatment patterns and survival among NHL patients. METHODS: We obtained a random sample of adult patients diagnosed between 2011 and 2015 from 11 population-based cancer registries in 10 SSA countries. ...
Herein, we examined treatment patterns and survival among NHL patients. METHODS: We obtained a random sample of adult patients diagno …
Safety of rapid rituximab infusion in adult cancer patients: a systematic review.
Lang DS, Hagger C, Pearson A. Lang DS, et al. Int J Nurs Pract. 2011 Aug;17(4):357-69. doi: 10.1111/j.1440-172X.2011.01950.x. Int J Nurs Pract. 2011. PMID: 21781215 Review.
The purpose of this study is to critically appraise, synthesize and present the best available evidence related to the safety of rapid rituximab infusion in adult non-Hodgkin lymphoma and chronic lymphocytic leukaemia patients. ...Proportional meta-ana …
The purpose of this study is to critically appraise, synthesize and present the best available evidence related to the safety of rapid ritux …
New developments in the management of diffuse large B-cell lymphoma.
Habermann TM. Habermann TM. Hematology. 2012 Apr;17 Suppl 1:S93-7. doi: 10.1179/102453312X13336169156014. Hematology. 2012. PMID: 22507791 Review.
Diffuse large B-cell lymphoma is the most common adult non-Hodgkin lymphoma and is potentially curable. Immunochemotherapy, R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) is the standard of care. ...The duration of cycle …
Diffuse large B-cell lymphoma is the most common adult non-Hodgkin lymphoma and is potentially curable. Immunoch …
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
Cho SK, McCombs J, Punwani N, Lam J. Cho SK, et al. Leuk Lymphoma. 2019 Oct;60(10):2464-2470. doi: 10.1080/10428194.2019.1581932. Epub 2019 Mar 8. Leuk Lymphoma. 2019. PMID: 30848975
Using the National Inpatient Sample (NIS) database from 2012-2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received autologous or allogeneic HSCT and examined complications as predictors of hospital cost. ...
Using the National Inpatient Sample (NIS) database from 2012-2014, we identified 1832 adult non-Hodgkin lymphoma …
14 results